Frequency Therapeutics Inc
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oli… Read more
Frequency Therapeutics Inc (KRRO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.173x
Based on the latest financial reports, Frequency Therapeutics Inc (KRRO) has a cash flow conversion efficiency ratio of -0.173x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.18 Million) by net assets ($99.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Frequency Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Frequency Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Frequency Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Frequency Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kwan's International Co., Ltd.
TWO:6101
|
-0.067x |
|
Patec Precision Industry Co Ltd
TW:2236
|
-0.089x |
|
Hf Foods Group Inc
NASDAQ:HFFG
|
-0.025x |
|
Kindly MD, Inc.
NASDAQ:NAKA
|
-0.028x |
|
Assertio Therapeutics Inc
NASDAQ:ASRT
|
-0.045x |
|
YEAH1 Group Corp
VN:YEG
|
-0.051x |
|
Xaar plc
PINK:XAARF
|
-0.016x |
|
Bioceltix S.A.
WAR:BCX
|
-0.184x |
Annual Cash Flow Conversion Efficiency for Frequency Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Frequency Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $160.41 Million | $-60.07 Million | -0.374x | +5.43% |
| 2023-12-31 | $169.91 Million | $-67.28 Million | -0.396x | -173.10% |
| 2022-12-31 | $-99.03 Million | $-53.65 Million | 0.542x | +320.81% |
| 2021-12-31 | $130.82 Million | $-32.09 Million | -0.245x | -4.50% |
| 2020-12-31 | $192.49 Million | $-45.19 Million | -0.235x | -214.83% |
| 2019-12-31 | $167.36 Million | $34.22 Million | 0.204x | -46.55% |
| 2018-12-31 | $-44.51 Million | $-17.02 Million | 0.382x | -22.42% |
| 2017-12-31 | $-29.64 Million | $-14.61 Million | 0.493x | -- |